Identification
Personal identification
- Full name
- Alan Ramsay
Citation names
- Ramsay, Alan
Author identifiers
- Ciência ID
- 0C15-01CB-7612
- ORCID iD
- 0000-0002-0452-0420
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
English | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) |
Education
Degree | Classification | |
---|---|---|
2013
Concluded
|
School of Cancer Sciences, Faculty of Life Sciences & Medicine, King’s College London. (Título de Agregado)
King´s College London, United Kingdom
"Understanding the immune checkpoint network in chronic lymphocytic leukemia and lymphoma to effectively combine immunotherapy
with targeted therapy." (THESIS/DISSERTATION)
|
Associate Professor and Lymphoma Programme Coordin |
2003
Concluded
|
BBSRC/CASE (Nestlé UK Ltd) PhD Studentship (Molecular & Cell Biology, Microbiology, Uni. of Aberdeen) (Doutoramento)
University of Aberdeen, United Kingdom
"Studying the molecular biology of novel probiotics for human health" (THESIS/DISSERTATION)
|
PhD awarded |
Affiliation
Others
Category Host institution |
Employer | |
---|---|---|
2013/12/01 - Current | Associate Professor/PI, Team Leader in Lymphoma Biology, Lymphoma Immunology group, Lymphoma Programme Coordinator, School of Cancer Sciences, Faculty of Life Sciences & Medicine, King’s College Londo | King´s College London, United Kingdom |
2009/10/01 - 2013/11/30 | Assistant Professor/PI, Team Leader, Barts Cancer Institute (a CRUK Centre of Excellence), Centre for Haemato-Oncology, Queen Mary University of London (QMUL). | Barts Cancer Institute, Queen Mary University of London, United Kingdom |
2006/10/01 - 2009/10/30 | Senior Postdoctoral Research Assistant with Prof. John G. Gribben, Centre for Haemato-Oncology, Barts Cancer Institute, QMUL. | Barts Cancer Institute, Queen Mary University of London, United Kingdom |
2003/10/01 - 2006/09/30 | Cancer Research UK Postdoctoral Research Fellow with Prof. Ian R. Hart, Centre for Tumour Biology, Barts Cancer Institute, London. | Barts Cancer Institute, United Kingdom |
1999/10/01 - 2003/09/30 | PhD research expedition, Nestlé Research Centre, Lausanne, Switzerland. BBSRC/CASE (Nestlé UK Ltd) PhD Studentship (Molecular & Cell Biology, Microbiology, University of Aberdeen) with Prof. Harry J. | University of Aberdeen, United Kingdom |
Projects
Grant
Designation | Funders | |
---|---|---|
2014 - 2022 | Investigating the immunomodulatory effects & MOA of combination immunotherapy in CLL and lymphoma.
N/A
Integration into Research Grant Fellow
|
|
2017 - 2021 | Investigating novel immunotherapies and targeting immunosuppressive CAFs in lymphoma.
N/A
Research Fellow
|
Concluded
|
2015 - 2021 | Immunomodulatory correlative science studies (T cell functional studies).
N/A
Integration into Research Grant Fellow
|
|
2015/05 - 2020/04 | Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia | National Cancer Institute |
2016 - 2020 | Understanding how immunomodulatory drugs affect tumour microenvironment (TME)/CAF-driven immune suppression (lymphoma).
N/A
Integration into Research Grant Fellow
|
|
2015 - 2019 | Combinatorial immune checkpoint blockade in B-cell malignancy (CLL, lymphoma).
N/A
Integration into Research Grant Fellow
|
|
2014/11 - 2018/11 | Investigating the immunomodulatory role of cancer-associated fibroblasts (CAFs) in chronic lymphocytic leukemia
14025
|
Bloodwise |
2016 - 2018 | Investigating the stromal/myofibroblast compartment in a DLBCL transgenic mouse model.
N/A
Integration into Research Grant Fellow
|
|
2014 - 2018 | Understanding the immune checkpoint network in chronic lymphocytic leukemia and lymphoma to effectively combine immunotherapy
with targeted therapy. Studying FRCs/cancer-associated fibroblasts (CAFs) in diffuse large B-cell lymphoma (DLBCL).
N/A
Integration into Research Grant Fellow
|
Outputs
Publications
Journal article |
|
Other
Other output |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2021 | Invited faculty and speaker at the prestigious 19th international workshops on CLL (wCLL 2021) - "Modelling the tumor microenvironment" | 19th international workshops on CLL (wCLL 2021) |
2021 | Invited speaker at the annual British Society of Immunology BSI meeting 2019, Cambridge Lymphoma Biology International Symposium 2021 | the annual British Society of Immunology BSI meeting 2019 |
2021 | Faculty, invited speaker, 16th International CLL/cancer workshops, Salzburg 2021 | 16th International CLL/cancer workshops |
2019 | Invited faculty and speaker at the prestigious 18th international workshops on CLL (iwCLL 2019) - Modelling the tumor microenvironment. | 18th international workshops on CLL (iwCLL 2019) |
2018 | Diffuse Large B-Cell Lymphoma Remodels the Fibroblastic Reticular Network That Acquires Aberrant Immunosuppressive Capabilities; Implications for the Regulation of Anti-Tumor Immunity in the Immuno-Oncology Era | 60th annual meeting of the ASH
American Society of Hematology (ASH)
|
2018 | Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial. | 60th annual meeting of the ASH
American Society of Hematology (ASH)
|
2018 | Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling. | 60th annual meeting of the ASH
American Society of Hematology (ASH)
|
2018 | Faculty, invited speaker, 14th International CLL/cancer workshops, Salzburg 2018 | 14th International CLL/cancer workshops |
2017/05 | Faculty, invited speaker, 2nd Nordic Meeting on Tumor Microenvironment in Lymphoma. Aarhus, May, 2017. Presentation: "Lymphoma-induced stromal reprogramming contributes to immunosuppression in the microenvironment; implications for optimizing combination immunotherapy". | 2nd Nordic Meeting on Tumor Microenvironment in Lymphoma
2nd Nordic Meeting on Tumor Microenvironment in Lymphoma (Aarhus, Denmark)
|
2016/09 | Invited speaker, Xth International workshop, German CLL study Group, Cologne, 2016. Presentation: "Targeting TME to optimize checkpoint inhibition" | Xth International workshop German CLL study Group
German CLL study Group (Cologne, Germany)
|
2016 | Invited speaker, 3rd Immunotherapy of Cancer Conference (ITOC), Munich 2016 | 3rd Immunotherapy of Cancer Conference (ITOC)
(Munich, Germany)
|
2015/12 | American Society of Hematology ASH, 57th Annual Meeting, Orlando, Florida, December 2015, Program: Scientific program: "Targeting the Tumor Microenvironment in Lymphoid Malignancies." https://ash.confex.com/ash/2015/webprogram/Session6166.html | American Society of Hematology ASH, 57th Annual Meeting |
2015 | Invited speaker, 2nd Immunotherapy of Cancer Conference (ITOC), Munich 2015 | 2nd Immunotherapy of Cancer Conference (ITOC)
(Munich, Germany)
|
2015 | Invited speaker, UK CLL forum, British Society for Hematology (BSH) annual scientific meeting, Edinburgh 2015 | UK CLL forum, British Society for Hematology (BSH) annual scientific meeting
British Society for Hematology (BSH) (Edinburgh)
|
2014 | Invited lecture, European Hematology Association (EHA) congress 2014, Milano, Scientific Working Group (Harnessing the immune system to treat chronic lymphocytic leukemia). | European Hematology Association (EHA) congress 2014
(Milano)
|
2014 | Invited lecture, Leukaemia & Lymphoma Research (LLR) symposium, British Society for Hematology BSH annual scientific meeting 2014, Birmingham (How lymphoma subverts the immune system) | Leukaemia & Lymphoma Research (LLR) symposium
British Society for Hematology BSH (Birmingham)
|
2012 | Presidential symposium, 17th Congress of the European Hematology Association (EHA), June 2012, Amsterdam. | |
2012 | Presidential symposium, 17th Congress of the European Hematology Association (EHA), June 2012, Amsterdam. |
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2022 - Current | Studying the impact of therapy on T cells in chronic lymphocytic leukemia
Supervisor
|
PhD (PhD) |
2018/10/01 - 2022/12/30 | Investigation of the validity of combination targeting of PAK family kinases in ovarian cancer
Co-supervisor
|
PhD (PhD) |
2018/10/01 - 2022/10/01 | Translational studies on the role of adipocytes in the tumor microenvironment in B cell lymphoma
Co-supervisor
|
|
2017/10/01 - 2021/12/01 | Investigating combination immunotherapy in chronic lymphocytic leukaemia
Supervisor
|
|
2016/10/01 - 2020/12/30 | Investigating how diffuse large B-cell lymphoma alters stromal cells in the tumour microenvironment
Supervisor
|
|
2016/01/04 - 2020/01/03 | Investigating the role of diffuse large B-cell lymphoma exosomes in the tumour microenvironment
Supervisor
|
|
2019/09/01 - 2019/09/30 | Investigating how chronic lymphocytic leukaemia modulates the fibroblastic reticular network and its contribution to immunosuppression
in the tumour microenvironment
Supervisor
|
|
2015/04/27 - 2019/03/26 | Investigating the effect of diffuse large B-cell lymphoma on endothelial cell phenotype and immunomodulatory functions
Supervisor
|
Event participation
Activity description Type of event |
Event name Institution / Organization |
|
---|---|---|
2012 - Current | • Presidential symposium, 17th Congress, EHA, June 2012, Amsterdam.
Symposium
|
17th Congress |
Committee member
Activity description Role |
Institution / Organization | |
---|---|---|
2015 - 2017 | American Society of Hematology, ASH Scientific Committee member: Lymphoid Neoplasia (2015-2017). |
Mentoring / Tutoring
Topic | Student name | |
---|---|---|
2014 - Current | Postgraduate Coordinator, School of Cancer Sciences, King’s College London. | Postgraduate Coordinator |
2013 - Current | Undergraduate Immunology (BSc, medical) and Postgraduate Teaching (lectures, tutorials, MRes project supervision), King’s College London. | Undergraduate Immunology (BSc, medical) and Postgraduate Teaching |
2015 - 2015 | Module Co-Leader (2nd year Immunology) "Immune system in health and disease." KCL. | 2nd year Immunology |
2011 - 2013 | Teaching Lead for the Centre for Haemato-Oncology, Barts Cancer Institute, QMUL | Teaching Lead for the Centre for Haemato-Oncology |
2006 - 2013 | Module Leader for MSc module: “Molecular targeted Therapies and Immunotherapy for Blood cancer”. Curriculum & examination design, lecturing & assessment. Undergraduate (BSc, medical) and Postgraduate teaching, Barts Cancer Institute, QMUL | Module Leader for MSc module |
Distinctions
Award
2021 | Cover images for Blood journal: Ioannou., et al 2021 |
2016 | Cover images for Blood journal: Smallwood et al 2016 |
2013 | Nature Reviews Clinical Oncology research highlight on Shanafelt & Ramsay Blood 2013 demonstrating the utility of the T-cell synapse bioassay during a phase II cancer patient clinical trial. (http://www.ncbi.nlm.nih.gov/pubmed/23546519) |
2012 | Top-ranking abstract for the European Hematology Association (EHA) 2012 |
2012 | Cover images for Blood journal: Ramsay et al., 2012 |
2012 | Invited to author a “Hematology in focus” article for the European Hematology Association (EHA) newsletter (November 2012 edition: (http://ehaweb.org/news/publications/eha-newsletter) |
2008 | Performance Recognition Reward 2008 (Queen Mary University of London). |
Other distinction
2014 | British Society for Haematology (BSH) Fellowship |
2009 | European Hematology Association (EHA) Fellowship grant |